Piramal Pharma Limited Stock

Equities

PPLPHARMA

INE0DK501011

Pharmaceuticals

Delayed NSE India S.E. 07:42:31 2024-04-30 am EDT 5-day change 1st Jan Change
143.6 INR +0.24% Intraday chart for Piramal Pharma Limited +1.66% +3.46%
Sales 2024 * 81.13B 972M Sales 2025 * 92.97B 1.11B Capitalization 190B 2.28B
Net income 2024 * 1.18B 14.11M Net income 2025 * 5.06B 60.62M EV / Sales 2024 * 2.76 x
Net Debt 2024 * 33.7B 404M Net Debt 2025 * 27.93B 335M EV / Sales 2025 * 2.34 x
P/E ratio 2024 *
192 x
P/E ratio 2025 *
37.6 x
Employees 6,295
Yield 2024 *
0.14%
Yield 2025 *
0.35%
Free-Float 26.56%
More Fundamentals * Assessed data
Dynamic Chart
Piramal Pharma Limited Receives Assessment Orders from the Office of the Navi Mumbai Municipal Corporation, Cess Department CI
Piramal Pharma Limited Receives Order from the Regional Provident Fund Commissioner, Thane South, Levying Damages of INR 1,120,932 Under Bombay Provincial Municipal Corporation (Cess on Entry of Goods) Rules, 1996 CI
Piramal Pharma Gets US FDA's Establishment Inspection Report for Riverview, US Facility MT
Piramal Pharma Forays into Men Grooming Products MT
Piramal Pharma Limited Announces the Launch of BOHEM Product Range CI
Transcript : Piramal Pharma Limited, Q3 2024 Earnings Call, Jan 31, 2024
Piramal Pharma Turns to Profit in Fiscal Q3 MT
Piramal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Piramal Pharma Solutions Commences Opening of Its Antibody-Drug Conjugate Manufacturing Expansion in Grangemouth, Scotland CI
FOCUS -Indian drug manufacturers benefit from Big Pharma interest beyond China RE
Piramal Pharma Gets US FDA's EIR Report After Bethlehem, USA Unit Inspection MT
Jefferies Adjusts Piramal Pharma's Price Target to INR135 From INR125, Keeps at Buy MT
Piramal Pharma Swings to Profit in Fiscal Q2 MT
Transcript : Piramal Pharma Limited, Q2 2024 Earnings Call, Oct 30, 2023
Piramal Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
More news
1 day+0.24%
1 week+1.66%
Current month+11.44%
1 month+11.44%
3 months+1.09%
6 months+55.30%
Current year+3.46%
More quotes
1 week
138.10
Extreme 138.1
146.40
1 month
129.10
Extreme 129.1
147.70
Current year
114.35
Extreme 114.35
149.00
1 year
70.75
Extreme 70.75
149.00
3 years
63.10
Extreme 63.1
200.00
5 years
63.10
Extreme 63.1
200.00
10 years
63.10
Extreme 63.1
200.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 20-03-03
President 51 20-06-09
Chief Operating Officer 60 20-04-04
Members of the board TitleAgeSince
Chairman 43 21-01-03
Director/Board Member 55 -
Director/Board Member 76 21-02-08
More insiders
Date Price Change Volume
24-04-30 143.6 +0.24% 3,126,412
24-04-29 143.3 +0.74% 3,241,028
24-04-26 142.2 +0.21% 2,286,342
24-04-25 142 +2.31% 2,203,137
24-04-24 138.8 -2.32% 2,992,953

Delayed Quote NSE India S.E., April 30, 2024 at 07:42 am EDT

More quotes
Piramal Pharma Limited is an India-based pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. The Company has approximately 17 global facilities and a global distribution network in over 100 countries. The Company's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC's complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain, anesthetics, injectable anti-infectives, and other therapies.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
143.6 INR
Average target price
168.4 INR
Spread / Average Target
+17.23%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. PPLPHARMA Stock